Sinopsis
New and exciting data presented each day during the conference and address the potential impact on current clinical practice.
Episodios
-
![Recent Advances in Acute Leukemia Management - Pinkal Desai, MD]()
Recent Advances in Acute Leukemia Management - Pinkal Desai, MD
20/12/2019 Duración: 21minRecent Advances in Acute Leukemia Management
-
![MRD Detection, Single Cell RNA Seq., Cell Free DNA, etc: Does it Impact Treatment? - Rafael Fonseca, MD]()
MRD Detection, Single Cell RNA Seq., Cell Free DNA, etc: Does it Impact Treatment? - Rafael Fonseca, MD
20/12/2019 Duración: 18minMinimal Residual Disease in Hematologic Malignancies: Testing Considerations and Challenges
-
![Measurable Residual Disease (MRD) in AML and ALL - Gail J. Roboz, MD]()
Measurable Residual Disease (MRD) in AML and ALL - Gail J. Roboz, MD
20/12/2019 Duración: 22minMinimal Residual Disease in Hematologic Malignancies: Testing Considerations and Challenges
-
![Panel Discussion: MDS and MPN - Gail J. Roboz, MD Pinkal Desai, MD Sangmin Lee, MD]()
Panel Discussion: MDS and MPN - Gail J. Roboz, MD; Pinkal Desai, MD; Sangmin Lee, MD
20/12/2019 Duración: 07minAdvances in TKI Therapy for CML: Navigating the Future Treatment Landscape
-
![Debate: CML in MMR: Should You Stop TKI Treatment? - Pinkal Desai, MD and Sangmin Lee, mD]()
Debate: CML in MMR: Should You Stop TKI Treatment? - Pinkal Desai, MD and Sangmin Lee, mD
20/12/2019 Duración: 15minAdvances in TKI Therapy for CML: Navigating the Future Treatment Landscape
-
![Approaches to Optimizing Care in CML in the Era of TKIs - Sangmin Lee, MD]()
Approaches to Optimizing Care in CML in the Era of TKIs - Sangmin Lee, MD
20/12/2019 Duración: 20minAdvances in TKI Therapy for CML: Navigating the Future Treatment Landscape
-
![Panel Discussion: Acute Myeloid Leukemia - Gail J. Roboz, MD Pinkal Desai, MD Sangmin Lee, MD]()
Panel Discussion: Acute Myeloid Leukemia - Gail J. Roboz, MD; Pinkal Desai, MD; Sangmin Lee, MD
20/12/2019 Duración: 10minLooking to the Future With Hope: Advances in the Treatment of AML
-
![Debate: Standard of Care for AML Patients ≥ 60 Years? - Pinkal Desai, MD and Sangmin Lee, mD]()
Debate: Standard of Care for AML Patients ≥ 60 Years? - Pinkal Desai, MD and Sangmin Lee, mD
20/12/2019 Duración: 17minLooking to the Future With Hope: Advances in the Treatment of AML
-
![Novel Therapies in AML II - Gail J. Roboz, MD]()
Novel Therapies in AML II - Gail J. Roboz, MD
20/12/2019 Duración: 19minLooking to the Future With Hope: Advances in the Treatment of AML
-
![Novel Therapies in AML I - Gail J. Roboz, MD]()
Novel Therapies in AML I - Gail J. Roboz, MD
20/12/2019 Duración: 18minLooking to the Future With Hope: Advances in the Treatment of AML
-
![Do Processing and Layers Matter? The Science and Clinical Experience of a Complete, Dehydrated, Placental-Derived Modality - George J. Koullias, MD, PhD and Andrew J. Rader, DPM]()
Do Processing and Layers Matter? The Science and Clinical Experience of a Complete, Dehydrated, Placental-Derived Modality - George J. Koullias, MD, PhD and Andrew J. Rader, DPM
19/12/2019 Duración: 01h02minThis webcast explores clinical cases illustrating the use of a dACM construct for the management of wounds.
-
![Navigating the Therapeutic Advances for Spinal Muscular Atrophy - Basil Darras, MD and Eric Cannon, PharmD, FAMCP]()
Navigating the Therapeutic Advances for Spinal Muscular Atrophy - Basil Darras, MD and Eric Cannon, PharmD, FAMCP
18/12/2019 Duración: 01h01minThis webcast discusses new and emerging therapies, with regard to their mechanisms of action, indications, efficacy, and cost-effectiveness.
-
![Optimizing Cardiovascular Outcomes in Type 2 Diabetes: Beyond A1C Goals - Susan Cornell, PharmD and Randolph V. Fugit, PharmD]()
Optimizing Cardiovascular Outcomes in Type 2 Diabetes: Beyond A1C Goals - Susan Cornell, PharmD and Randolph V. Fugit, PharmD
17/12/2019 Duración: 01h29minRecorded during the AHSP Midyear Meeting, this webcast discusses translating outcomes from T2DM cardiovascular trials into clinical practice to implement individualized management strategies for patients with T2DM at high risk of or with a history of CVD.
-
![Innovations in Regenerative Medicine Therapy for Severe Burns and Other Complex Skin Defects - Jeffrey E. Carter, MD Angela L. Gibson, MD Jeffrey S. Litt, DO]()
Innovations in Regenerative Medicine Therapy for Severe Burns and Other Complex Skin Defects - Jeffrey E. Carter, MD; Angela L. Gibson, MD; Jeffrey S. Litt, DO
12/12/2019 Duración: 42minThis webcast explores research, science and clinical evidence surrounding the evolution of regenerative medical approaches to burn healing.
-
![Biosimilars and Oncology Clinical Pathways: Perfect Together - Gary H. Lyman, MD]()
Biosimilars and Oncology Clinical Pathways: Perfect Together - Gary H. Lyman, MD
10/12/2019 Duración: 51minThis webcast discusses considerations for switching patients from biologics to biosimilars in clinical practice where appropriate guided by clinical practice guidelines and pathways.
-
![Navigating Rapid Change in Ovarian Cancer: PARP Inhibitors in Clinical Pathways - Alexander B. Olawaiye, MD]()
Navigating Rapid Change in Ovarian Cancer: PARP Inhibitors in Clinical Pathways - Alexander B. Olawaiye, MD
10/12/2019 Duración: 39minThis webcast discusses current guideline recommendations for ovarian cancer and strategies to improve the incorporation of recommendations into clinical pathways for ovarian cancer treatment.
-
![Prostate Cancer: Clinical Guidelines, Novel Therapies, and the Constant State of Therapeutic Uncertainty - Atish D. Choudhury, MD, PhD]()
Prostate Cancer: Clinical Guidelines, Novel Therapies, and the Constant State of Therapeutic Uncertainty - Atish D. Choudhury, MD, PhD
10/12/2019 Duración: 42minThis webcast discusses the impact of integrating new and innovative therapies into clinical guidelines and pathways.
-
![Acute Myeloid Leukemia: Navigating Treatment Paradigm Shifts and Disease Heterogeneity - Amir T. Fathi, MD]()
Acute Myeloid Leukemia: Navigating Treatment Paradigm Shifts and Disease Heterogeneity - Amir T. Fathi, MD
10/12/2019 Duración: 55minThis webcast discusses recent therapeutic advances, resource utilization data, and current guidance into AML clinical pathways discussions.
-
![Strategies for NSCLC: Clinical Pathways in the Era of Biomarker-Driven Care - David Jackman, MD]()
Strategies for NSCLC: Clinical Pathways in the Era of Biomarker-Driven Care - David Jackman, MD
10/12/2019 Duración: 34minThis webcast summarizes the role of genetic mutations and patient-specific biomarkers in therapeutic selection and pathway design for NSCLC.
-
![Chronic Myeloid Leukemia: Keeping Up with Evolving Treatment Landscapes in Clinical Pathways - Gabriela Hobbs, MD]()
Chronic Myeloid Leukemia: Keeping Up with Evolving Treatment Landscapes in Clinical Pathways - Gabriela Hobbs, MD
10/12/2019 Duración: 32minThis webcast examines the most recent evidence-based guidelines to optimize individualized tyrosine kinase inhibitor (TKI) selection for CML patients based on disease phase, treatment history, genetic mutation profile, and comorbidities.
